Video

Dr. Agarwal on the TALAPRO-2 Trial in mCRPC

Neeraj Agarwal, MD, associate professor, Division of Oncology, Department of Medicine, University of Utah School of Medicine; and director, Genitourinary Oncology Program, Oncology Division, co-leader, Urologic Oncology Multidisciplinary Program, associate director of Clinical Trials, Huntsman Cancer Institute, discusses part 1 findings from the phase III TALAPRO-2 trial in metastatic castration-resistant prostate cancer.

Neeraj Agarwal, MD, associate professor, Division of Oncology, Department of Medicine, University of Utah School of Medicine; and director, Genitourinary Oncology Program, Oncology Division, co-leader, Urologic Oncology Multidisciplinary Program, associate director of Clinical Trials, Huntsman Cancer Institute, discusses part 1 findings from the phase III TALAPRO-2 trial in metastatic castration-resistant prostate cancer.

Thus far, in part 1 of the TALAPRO-2 trial, data showed that the optimal 0.5 mg dose of talazoparib (Talzenna) was found to be very safe and was associated with preliminary efficacy when in combination with enzalutamide (Xtandi), Agarwal explains.

The ultimate goal of part 2 of this study is to improve survival in these patients, not only in terms of radiographic progression-free survival, but also overall survival. The trial is enrolling more than 800 patients worldwide, and investigators hope to see encouraging data that will change the standard of care for this patient population.

<<< 2019 ASCO Annual Meeting

Related Videos
Omid Hamid, MD
FRCSI, FRCSEd, medical director, Thoracic Cancer Program, and associate executive director, AdventHealth Cancer Institute
Benjamin P. Levy, MD, clinical director, Medical Oncology, Johns Hopkins Sidney Kimmel Cancer Center at Sibley Memorial Hospital; and associate professor, oncology, Johns Hopkins University School of Medicine
Russell Hales, MD, director, Thoracic Oncology Multidisciplinary Program, associate professor, clinical radiation oncology and molecular radiation sciences, and director, thoracic multidisciplinary clinic, John Hopkins University School of Medicine
Estelamari Rodriguez, MD, MPH, associate director, Community Outreach – Thoracic Oncology, Sylvester Comprehensive Cancer Center
Kathleen N. Moore, MD, MS
Dana M. Chase, MD
Misty D. Shields, MD, PhD, assistant professor, clinical medicine, Department of Medicine, Division of Hematology/Oncology, Indiana University (IU) School of Medicine; and associate member, Experimental and Developmental Therapeutics, IU Melvin and Bren Simon Comprehensive Cancer Center
Corey J. Langer, MD, director, Thoracic Oncology, Penn Medicine; and professor, medicine (hematology-oncology), the Hospital of the University of Pennsylvania, Perelman School of Medicine
R. Wendel Naumann, MD, professor and director of gynecologic oncology research, and associate medical director of clinical trials, Levine Cancer Institute, Atrium Health